A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
PHASE1CompletedINTERVENTIONAL
Enrollment
54
Participants
Timeline
Start Date
Not specified
Study Completion Date
June 30, 1993
Conditions
HIV Infections
Interventions
BIOLOGICAL
HIVAC-1e
BIOLOGICAL
gp160 Vaccine (MicroGeneSys)
Trial Locations (1)
14642
Univ. of Rochester AVEG, Rochester
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000683 - A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter